AGLE Stock Price - Aeglea BioTherapeutics Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch

Aeglea BioTherapeutics (AGLE) doses first patients in two early stage lung cancer studies evaluating pegzilarginase as single agent and in combination with Merck's Keytruda.

Apr. 3, 2018 at 8:53 a.m. ET
on Zacks.com

Your Daily Pharma Scoop: Portola's New Interim Data, Lantheus Announces Promising Data For LMI 1195, Kura Tumbles On Update

Mar. 13, 2018 at 5:27 p.m. ET
on Seeking Alpha

Aeglea Bio's pegzilarginase shows encouraging action in patients with arginase 1 deficiency

Mar. 13, 2018 at 9:47 a.m. ET
on Seeking Alpha

Biotech Forum Daily Digest For March 12th

Mar. 12, 2018 at 10:47 a.m. ET
on Seeking Alpha

Key events next week - healthcare (continued #4)

Mar. 9, 2018 at 10:01 a.m. ET
on Seeking Alpha

Aeglea Bio sells off after presentation on lead candidate AEB1102; shares down 11%

Jan. 23, 2018 at 3:40 p.m. ET
on Seeking Alpha

Weekly CFO Buys Highlight

Dec. 17, 2017 at 2:24 p.m. ET
on GuruFocus.com

Aeglea Biotherapeutics (AGLE) Presents At BMO Capital Markets 2017 Prescriptions For Success Healthcare Conference - Slideshow

Dec. 15, 2017 at 1:30 p.m. ET
on Seeking Alpha

Your Daily Pharma Scoop: Gilead's Potential, Celgene CAR-T Candidate, Cellectar Soars

Dec. 7, 2017 at 8:00 a.m. ET
on Seeking Alpha

Aeglea Biotherapeutics (AGLE) Presents At Society For Immunotherapy Of Cancer - Slideshow

Nov. 13, 2017 at 12:23 p.m. ET
on Seeking Alpha

10-Q: AEGLEA BIOTHERAPEUTICS, INC.

Aug. 9, 2017 at 4:12 p.m. ET
on Edgar Online - (EDG = 10Q, 10K)

Stocks to watch next week

Aug. 5, 2017 at 9:42 a.m. ET
on Seeking Alpha

Endo Asked to Withdraw Pain Drug-Opana ER by FDA, Stock Down

Jun. 9, 2017 at 9:06 a.m. ET
on Zacks.com

Aeglea BioTherapeutics Prices Public Offering of Common Stock

Apr. 18, 2018 at 10:50 p.m. ET
on GlobeNewswire

Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock

Apr. 17, 2018 at 4:02 p.m. ET
on GlobeNewswire

Aeglea BioTherapeutics Presents New Phase 1/2 Trial Data Demonstrating Clinically Relevant Treatment Effects in Arginase 1 Deficiency Patients at the 2018 ACMG Annual Clinical Genetics Meeting

Apr. 12, 2018 at 7:00 a.m. ET
on GlobeNewswire

Aeglea BioTherapeutics to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at 2018 AACR Annual Meeting

Apr. 5, 2018 at 8:01 a.m. ET
on GlobeNewswire

Aeglea BioTherapeutics to Present New Phase 1/2 Trial Results in Arginase 1 Deficiency at the 2018 ACMG Annual Clinical Genetics Meeting

Apr. 3, 2018 at 8:02 a.m. ET
on GlobeNewswire

Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA(R) (Pembrolizumab) Combination Trials

Apr. 2, 2018 at 8:02 a.m. ET
on GlobeNewswire

Aeglea BioTherapeutics Appoints Dr. Ivana Magovcevic-Liebisch to Board of Directors

Mar. 26, 2018 at 8:00 a.m. ET
on GlobeNewswire

Aeglea BioTherapeutics to Present at 17th Annual Needham Healthcare Conference

Mar. 20, 2018 at 8:01 a.m. ET
on GlobeNewswire

Aeglea BioTherapeutics Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency and Reports Q4 and Full Year 2017 Financial Results

Mar. 13, 2018 at 7:01 a.m. ET
on GlobeNewswire

Aeglea BioTherapeutics Doses First Uveal and Cutaneous Melanoma Patients in Phase 1 Cohort Expansions with Pegzilarginase

Mar. 8, 2018 at 8:00 a.m. ET
on GlobeNewswire

Aeglea BioTherapeutics to Present Adult Repeat Dose Data at 2018 Annual Meeting of The Society for Inherited Metabolic Disorders

Mar. 6, 2018 at 4:21 p.m. ET
on GlobeNewswire

Aeglea BioTherapeutics to Present Preclinical Data at 2018 Keystone Symposia Tumor Metabolism Conference

Jan. 18, 2018 at 4:06 p.m. ET
on GlobeNewswire

Aeglea BioTherapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference

Dec. 7, 2017 at 4:06 p.m. ET
on GlobeNewswire

Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102)

Nov. 29, 2017 at 8:02 a.m. ET
on GlobeNewswire

Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results

Nov. 7, 2017 at 4:06 p.m. ET
on GlobeNewswire

Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov. 2, 2017 at 4:08 p.m. ET
on GlobeNewswire

Aeglea BioTherapeutics Announces Clinical Collaboration with Merck to Evaluate the Combination of Aeglea's AEB1102 (pegzilarginase) with Merck's KEYTRUDA(R) (pembrolizumab) for the Treatment of Small Cell Lung Cancer

Oct. 16, 2017 at 8:01 a.m. ET
on GlobeNewswire

Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency

Sep. 6, 2017 at 7:02 a.m. ET
on GlobeNewswire

Aeglea BioTherapeutics to Present at the 2017 Wells Fargo Healthcare Conference

Aug. 31, 2017 at 4:06 p.m. ET
on GlobeNewswire

Aeglea BioTherapeutics Announces Leadership Change

Jul. 20, 2017 at 4:03 p.m. ET
on GlobeNewswire

Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer. It develops pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX. (See Full Profile)

Sell
Under
Hold
Over
Buy

Number of Ratings 4 Full Ratings

Benzinga's Top Initiations

May. 2, 2016 at 9:47 a.m. ET
on Benzinga.com

Name	Chg %	Market Cap
Omeros Corp.	2.78%	$696.28M
Ono Pharmaceutical Co. Ltd. ADR	0.00%	$12.47B
Onconova Therapeutics Inc.	-8.66%	$10.1M
Oncolix Inc.	26.76%	$3.96M

Competitor Data Provided By

DJIA F	24,561	147	0.60%
S&P F	2,686.50	15.25	0.57%
NASDAQ F	6,698.75	31.75	0.48%
Gold	1,326.70	2.70	0.20%
Silver	16.65	-0.008	-0.05%
Crude Oil	68.81	0.17	0.25%

Aeglea BioTherapeutics Inc.

$ 8.45

Customize MarketWatch

No Items in Watchlist

No Saved Watchlists

Uh oh

No Recent Tickers

Aeglea Bio Therapeutics started at outperform with $37 stock price target at Evercore ISI

Aeglea BioTherapeutics trading at $9.91, below price range of $10

Stocks

Columns

Authors

Topics

^$ 8.45